


**CUMULATIVE INDEX**

**VOLUME 8, NUMBERS 1-3**

**MARCH-SEPTEMBER, 1965**



## CUMULATIVE INDEX

**Boldface type** shows inclusive page numbers of articles or extensive discussion.

**A**борtion  
habitual, 92-93  
uterine deformity as cause, 50, 52

Acromegaly, effect on fertility, 74

Adenohypophysis. *See* Pituitary, anterior

Adenomyosis, estrogen excretion in, 559-560

Adolescence  
adults, identification with, in, 149  
attitudes towards, 150-158  
of adolescent, 150-153  
of parents, 153-155  
of physician, 155-158  
"body image," development of, 147  
conflicts, oedipal, 148-149  
disillusionment, process of, 149-150  
dysmenorrhea, response to, 152-153, 228, 230, 231-232  
physiology, changes in, 147-150  
response to, 151

SLE as cause, 277, 315

Adrenalcortical hormones, 526-527

Aldosterone  
in nonpregnant female, 526-527, 544  
in pregnancy, 544-545  
and relation to sodium ingestion, 544

Amenorrhea  
bioassays, use of, in determining cause of, 106-107  
without demonstrable disease, 101  
from failure of gonadotropin secretion, 523  
"hypothalamic," 77, 102-103  
"mother-in-law," 102  
persistent lactation, 74, 75-77  
*See also* Chiari-Frommel syndrome  
primary, with anovulation, 60-62  
clinical types of, 61-62  
secondary, due to adrenal disorders, 83  
temporary, 102  
and vesicocervical fistula, 478  
"war," 102

Anastomosis  
to intact bowel, 730, 733-734  
ureterocutaneous, 726-730  
bilateral side-to-side, 729-730, 731, 732  
clinical evaluation, 726-727  
complications of, 727

flank ureterostomy, 728-729  
operative techniques, 727-730  
radiation effect on, 734

ureterointestinal, 730, 733-754  
clinical evaluation, 730, 733-736  
complications of, 733-734  
to intact bowel, 730, 733-734  
to large bowel above colostomy, 734  
operative technique, 737-740  
operative techniques, 736-754  
pyeloileal cutaneous, 735-736  
operative technique, 746, 748-754  
wet colostomy, 734  
operative technique, 737-740

Anemia  
in rheumatoid arthritis, 288  
in SLE, 317, 318

Anencephaly, decreased estriol excretion in, 560

Anovulation and primary amenorrhea, 60-62

Anticoagulant therapy, after pelvic surgery, 637

Anuria  
postoperative, 414, 417-421  
management of, 418-421  
decompression, 420-421  
by intubated ureterostomy, 421  
by nephrostomy, 421  
by pyelostomy, 421  
PSP test, 419  
removal of ligature, 420

Artificial insemination  
donor, 135  
homologous, 27-29, 135  
indications for, 27-28, 135

Aspermia, 121

Autoimmunity, 94-95, 272-273  
mechanisms of, 272-273  
and rheumatoid arthritis, 274-275

**B**ladder  
bisection of, 484-485  
flap, 435-436, 437-438  
injuries to, 376, 377, 378  
reimplantation of ureter into, 435-436  
vesicovaginal fistula, 485, 486-492

---

Pages 1-248, March issue; pages 249-504, June issue; pages 505-800, September issue.

Bowel  
preoperative preparation, 632  
postoperative care, 638-639

**C**ancer  
cervical, 392-395, 616-612  
paravaginal hysterectomy for, 616  
with lymph node dissection, 616  
with X-ray therapy to nodes, 616  
radiation therapy for, 616  
combined with surgery, 621  
comparison with surgical therapy, 617-619  
complications, 393, 394, 617-618  
radioresistant, 621-623  
determination of inoperability, 622-623  
radiosensitivity of tumors, 619  
radiation response, 620  
sensitization response, 619-620  
recurrent, 622, 705  
surgical treatment of, 616, 617  
*See also specific operations*  
abdominal vs. vaginal approach, 676-677  
compared with radiation therapy, 617-619  
complications, 617, 618, 619  
with radiation, 621  
Schauta-Amreich operation for, 676-703  
total pelvic evisceration, 705-723  
Wertheim operation for, 616  
endometrial, 623-624  
genital tract, carcinoma in situ, 757-769  
classification, 757  
incidence after cervical conization, 757-760  
incidence after hysterectomy, 760  
multicentric foci of origin, 761-764  
recurrent, 764-766  
diagnosis, 765-766  
surgical technique, 766-768  
residual disease, 757-761  
radiation treatment of, 760-761  
surgical treatment of, 761  
ovarian, 386  
pelvic  
radical surgery for, 611-625  
of the ureter, 392-395  
urethral, 365-366  
vaginal, 614-616  
radiation therapy for, 615, 616  
radical surgery for, 615, 616  
ratio of, to cervical malignancy, 614  
vulvar, 612-614  
electrocoagulation, 614  
irradiation of nodes, 614  
radical surgery for, 612-614  
mortality, 613-614

Carcinoma. *See Cancer*

Caruncle of urethra, 363-364

Cervix  
anatomy and physiology of, 15-16  
cancer of, 392-395, 616-623  
carcinoma in situ following conization, 757-760  
endocervical gland, 16, 17  
mucus  
arborization of, 18, 22-23  
bacteriology of, 23  
biochemistry and infertility, 19  
characteristics, 16-19, 22  
electrocauterization, 20, 23  
evaluation of, 22-23  
postcoital test for, 23-25  
*See also Postcoital test*  
spermatozoa compatibility, in vitro test of, 25  
pH, 23  
spinnbarkeit, 16, 17, 22  
viscosity, 16

Chiari-Frommel syndrome, 74, 75-77

Chromatography, gas liquid  
for measuring urinary estriol excretion, 517-518

Collagen, 334  
diseases, 273-277  
characteristics of, 273-274  
in pregnancy, 276-277  
*See also specific collagen diseases*

Colostomy  
postoperative care, 639  
wet, 734  
operative technique, 737-740

Compound F. *See Cortisol*

Conization, cervical  
incidence of carcinoma following, 757-760

Contraception  
criteria for, 96  
immunologic aspects, 96-97  
*See also Infertility, immunologic causes of*

Corticosterone, 543

Cortisol, 526, 543-544  
in nonpregnant state, 543  
in pregnancy, 543-544

Cortisone, 543  
 Cyst, suburethral, 366-367

**Delivery**  
 effect of polyarteritis nodosa, 331  
 effect of rheumatoid arthritis, 295  
 of sclerodermic patient, 283-284  
 unexplained premature, and estriol levels in, 552, 553

**Depression, in gynecologic patient, 236-239**

**Dermatomyositis, 304-306**  
 age incidence, 304  
 clinical picture, 304-305  
 laboratory findings, 305  
 pathology, 304  
 and pregnancy, 305-306  
 prognosis, 305  
 and Raynaud's phenomenon, 304  
 sex incidence, 304  
 treatment, 306  
 adrenal steroids in, 306

**Diabetes and pregnancy**  
 urinary estriol excretion tests, 518

**Doctor-patient relationship**  
 in gynecology, 174-183, 189-190  
 with adolescent, 155-158  
 dangers involved in, 184-195  
 psychopathology, 184-190  
 determinants of, 176-182  
 problem patient, 190-193

**Dribbling. *See* Urinary incontinence, dribbling**

**Dysmenorrhea**  
 adolescent response to, 152-153  
 periodic, 235  
 psychological factors in, 222-223

**Ehlers-Danlos syndrome, 337**

**Electrocauterization, effect on cervical mucus, 20, 23**

**Electrocoagulation therapy for urethrovaginal fistulas, 424**  
 for vesicovaginal fistulas, 465-482

**Electrolytes, postoperative replacement, 638**

**Endocrine activity**  
 in nonpregnant female, 521-527  
 of placenta, 580-597  
 of pregnancy, 528-547

**Endometriosis, 55-56, 66-67**  
 diagnosis of, 55-57  
 distortion of anatomic relations of pelvis, 377  
 and sterility, incidence of, 55, 66-67

treatment of, 56, 67  
 of ureter, 386

**Endometrium, cancer of, 623-624**

**Enovid, for suppression of lactation, 517**

**Enzymes, oxytocin inactivating, 530**

**Epispadias, 357**

**Erythroblastosis**  
 increase in HCG level, 533  
 placenta in, 557  
 urinary estriol levels in, 556-557

**Estriol**  
 in abnormal pregnancy, 550, 552-560  
 adenomyosis, 559-560  
 anencephaly, 560  
 erythroblastosis, 556-557  
 in fetal death, 560  
 in hydatidiform mole, 560  
 placental insufficiency in, 560  
 in pregnant diabetic, 558-559  
 in pyelonephritis, 555-556  
 in spontaneous premature membrane rupture, 552-554  
 in normal pregnancy, 550-552  
 in toxemia of pregnancy, 554-555  
 in twin births, 558  
 in unexplained premature delivery, 552, 553

**Estrogen(s)**  
 in nonpregnant female, 523-525  
 in adolescent, 539  
 adrenal, 523  
 bioassay of, 524-525  
 chemical measurement of, 524  
 effects of, 525  
 estradiol-17 $\beta$ , 523  
 estriol, 523  
 estrone, 523  
 in menstrual cycle, 539  
 ovarian, 523-525  
 in pregnant female, 539-541  
 combined with progestational agents, 567  
 estradiol-17 $\beta$ , 540

**Fallopian tube. *See* Tubes, fallopian**

**Fetal death**  
 artificially induced and urinary excretion of hormones, 581  
 associated with missed abortion, 518-519  
 indications of impending, 518  
 urinary estriol levels in, 560

**Fetomaternal exchange of steroids, 518-519**

Fetus  
 death of. *See* Fetal death  
 effect of drug therapy on, 295, 300  
 effect of SLE on, 312, 313  
 estriol excretion and size of, 518, 541  
 source of growth hormone in, 535-536

Fibroids, 386

Fistulas  
 obstetric, 376, 472-482, 483  
 postcesarean, 472-482  
 operative management, 472-473  
 postoperative management, 473  
 preoperative management, 472  
 postoperative, 376, 392, 393-394  
 rectovaginal, following radical pelvic surgery, 780  
 urethrovaginal, 374, 391, 392, 415  
 differentiation of vesicovaginal, 417, 418  
 treatment of, 421-440  
 conservative, 422, 423-428  
 cystoscopy with insertion of catheter, 424, 427, 428  
 electrocoagulation, 424  
 watchful waiting, 422, 423-424, 425, 426  
 restoration of ureteral continuity, 434-438  
 closure of fistula with suture, 434-435  
 by downward displacement of kidney and ureter, 436  
 reimplantation of ureter into bladder, 435-436  
 by bladder flap, 435-436, 437-438  
 by ureteroneocystotomy, 435, 776, 777  
 suppression of further secretion of urine, 429-432, 433  
 intentional ligation of ureter, 432  
 by nephrectomy, 429-432, 433  
 ureteroplasty, 439-440  
 transureteroureteral anastomosis, 439  
 ureteroileocystoplasty, 439-440, 776, 778  
 ureteroureteral anastomosis, 439  
 urinary diversion, 432, 434, 711-715, 726-755  
 use of isolated segment of ileum, 439  
 by nephrostomy, 432  
 by ureteroileostomy, 434

by uretersigmoidostomy, 434, 730  
 by cutaneous ureterostomy, 432, 434, 726-730

vesicocervical, 475, 478, 479  
 occurrence of symptoms, 475, 478  
 menuria, 478-479  
 urinary leakage, 478  
 surgical repair of, 479

vesicocervicovaginal, 473-475  
 case study, 475  
 catheterization for, 475  
 surgical repair, 475, 476, 477

vesicouterine, 480-482

vesicovaginal  
 coagulation therapy for, 465-482  
 criteria for use, 466-467  
 results, 469, 470  
 technique of, 468-469  
 anesthesia for, 468  
 catheterization, 469  
 cystoscopic evaluation, 467-468  
 differentiation of ureterovaginal, 417, 418  
 following diverticulectomy, 374  
 following gynecologic surgery, 483, 484  
 following pelvic irradiation, 779  
 following total hysterectomy, 376, 465-466, 624, 706, 775-779  
 analysis of cases, 466-467  
 prevention of, 376-382  
 repair of, 776-779  
 methods of repair, 492-493  
 multiple operations, 483-484, 485  
 after pelvic surgery, 483, 775-779  
 site of fistula, 483  
 postcesarean, 472, 473  
 preoperative insertion of catheter, 396  
 principles of management, 485-486  
 transvesical approach to, 483-494  
 postoperative care, 489  
 results, 489, 492  
 technique for, 484-485, 486-489, 490-491

**G**alactopoiesis, 601, 604-605  
 Gas liquid chromatography, 517-518  
 Gonadotropin(s), 532-533  
 assay of, 91-92, 521-522  
 chorionic (HCG), 532-533  
 during pregnancy, 533  
 follicle-stimulating hormone (FSH), 521, 523, 531

in reproductive process, 532  
 human pituitary gonadotropin (HPG), 522  
 interstitial cell-stimulating hormone (ICSH), 521, 523, 531  
     in reproductive process, 532  
 luteinizing hormone (LH), 521, 531  
 mechanism of secretion, 522-523  
     failure of, 523  
 in nonpregnant female, 521-523  
 pituitary, 532  
 in postmenopausal women, 522  
 production of, 521  
 prolactin (luteotropin), 521  
 Gonorrheal urethritis, 359-360  
     laboratory diagnosis, 359  
     symptoms, 359  
     treatment, 359-360  
 Growth hormone, 531  
     during pregnancy, 535-536  
     effect on lactation, 602  
**H**emorrhage, and shock in preoperative course, 636-637  
 Hemorrhoids of urethra, 366  
 Homograft, placenta as, 263-269  
 Hormone(s)  
     adrenocorticotrophic (ACTH), 526, 531  
         increase in pregnancy, 533-535  
     adrenal cortical, 526-527, 531, 542-545  
         glucocorticoids, 543-544  
             See also Cortisol; Cortisone  
         mineralocorticoids, 544-545  
             See also Aldosterone  
         sex steroids, 527, 545  
     anterior pituitary, 522, 531-536  
         feedback effect, 531  
         See Gonadotropins; Growth hormone  
     antidiuretic (ADH), 529, 530-531  
         vasopressor effect, 531  
     estrogen. See Estrogen(s); Estriol  
     gonadotropic. See Gonadotropin(s)  
     luteotropic (LTH), 531  
         in pregnancy, 535-536  
     ovarian, 522, 523-525  
         See Estriol; Estrogen(s); Progesterone; Relaxin  
     parathyroid, 546-547  
     placental, 541-542  
     producing glands, 528  
     thyroid, 527, 531  
         during pregnancy, 536, 545-546  
     Hurler's syndrome, 337  
     Hydatidiform mole, estriol levels in, 560  
     Hydronephrosis, 386  
     Hydrourete, 386  
     Hyperchloremic acidosis, 733  
     Hyperthyroidism  
         maternal, 77  
         menstruation, as affected by, 79  
     Hypophysectomy, and effect on sperm motility, 125  
     Hypospadias, 356-357  
     Hypothalamus  
         and pregnancy, 528-529  
         relationship to pituitary, 528  
         role of, in gonadotropic secretion, 522  
     Hypothyroidism  
         menstruation, as affected by, 79  
         treatment of maternal, 78  
     Hysterectomy  
         for cervical cancer, 393, 616  
         carcinoma in situ following, 760  
         complications following, 393-394, 700-701, 774-782  
         gastrointestinal, 780  
         lymphocysts, 779-780  
         thromboembolic disease, 780, 782  
         urinary tract, 775-779  
         extensive abdominal and pelvic lymphadenectomy, 659-675  
         blood loss during, 661, 667, 668, 671  
         surgical technique, 660-675  
         radical vaginal (Schauta-Amreich operation), 676-703  
         complications, 700-701  
         end results, 701, 702, 703  
         indications for, 677-678  
         postoperative mortality, 701  
         postoperative treatment, 699-700  
         preoperative investigation, 678  
         preoperative radium treatment, 677  
         preparation of patient, 678  
         surgical technique, 678-699  
         subtotal, 383  
         supracervical, 384  
         total abdominal  
             for benign disease, 376-382, 383-384  
             technique, 379-381  
             ureteral injury, 383-384  
             for cancer of endometrium, 623-624  
         total vaginal, for benign disease, 383

Hysteria, 163-164, 239-242  
 clinical management of hysterical breakdown, 241-242  
 clinical picture, 240-241  
 and hysterical personality, 163-164

Hysterosalpingography, 35-41  
 interpretation of films, 37-41  
 pregnancy after, incidence of, 40-41  
 radiation, effect on ovaries, 39-40  
 technique, 36-37, 38, 39

**I**mmunologic paralysis, 272

Infection  
 of periurethral glands, 362-363  
 following radical surgery, 637  
 urethral, 359-363

Infertility  
 adrenal glands, effect on, 81-87  
 tests, clinical, of dysfunction, 83-86  
 anterior pituitary gland, effect on, 73-77  
 acromegaly, 74  
 Chiari-Frommel syndrome, 74, 75-77  
 gonadotropins, deficiency of, 74, 75  
 "hypothalamic amenorrhea," 77  
 panhypopituitarism, 74

cervical factor in, 15-29  
*See also* Cervix  
 investigation of, 19-25  
 characteristics of mucus, 16-19  
 related conditions, 20-21  
 chronic cervicitis, 21, 23  
 electrocauterization, 20, 21, 23  
 estrogen deficiency, 21  
 lesions, cervical, 21, 26-27  
 retrodisplacement, 20, 26  
 uterus, prolapse of, 20, 26  
 vaginal, 20, 26  
 tests for determination of, 23-25  
 treatment of, 26-31  
 coitus, poor techniques of, 103-104  
 improvement of, 26  
 dietary factors, effect of, 103  
 emotional aspects of, 100-114  
 diagnosis, methods of, 104-113  
 psychometric testing, 108-113  
 tests, 106. *See also* Postcoital test; Tubes, fallopian, insufflation  
 psychogenic factors, 102-103  
 treatment of, 113

endometriosis in, 55-56, 66-67  
*See also* Endometriosis

immunologic causes of, 25-26, 93-96

ABO blood incompatibility, 93-94  
 sperm-agglutinating antibodies, 95  
 autoimmunity, 94-95  
*See also* Contraception, immunologic aspects

male, 128-131  
 history, 128, 132-133  
 physical examination, 128-129  
 cryptorchism, 130  
 surgical treatment of, 139-140

endocrine disturbances, 130  
 genetic disturbances, 130  
 mumps orchitis, 130

semen examination. *See* Semen examination  
 sperm ducts, blocked, 130  
 surgical treatment of, 139

varicocele, 130  
 surgical treatment of, 138

vas deferens, congenital absence of, 130

treatment of, 132-140  
 medical, 133-138  
 endocrine methods, 135-138  
 insemination, artificial, 135  
*See also* Artificial insemination  
 nutritional measures, 133  
 semen, cultures of, 134  
 sperm, storing and concentration of, 134-135  
 psychologic measures, 133  
 surgical, 138-140

metabolic factors, 103  
 myomas, uterine, effect on, 52  
 ovarian factor in, 58-71  
*See also* Ovary  
 spermatogenesis, failure of, 103  
*See also* Infertility, male  
 thyroid function and, 77-81, 103  
 miscarriages, incidence of, 77  
 unexplained, 93-96

**J**audice  
 and remission of rheumatoid arthritis, 293-294

Johnson Temperament Analysis, 108-113

**L**actation  
 anterior pituitary factors, 602  
 effect of oxytocin on, 529  
 galactopoiesis, 601, 604-605

lactogenesis, 601-603  
 milk ejection reflex, 529, 601, 603  
 ovarian hormones in, 601-602  
 sucking reflex, 603-604  
 suppression of, 517, 605-606  
 theories of mechanism, 602-603

Lymphocysts following radical pelvic surgery, 779-780

**M**arfan syndrome, 336-342  
 basic defect, 338-339  
 chromosomal abnormality, 339  
 elastic-fiber defect, 338  
 metabolic defect, 339, 342  
 clinical picture in, 339-340  
 diagnosis, 342  
 dissecting aortic aneurysm, 342-346  
 animal studies, 344  
 case studies, 345-346  
 effect on blood vessels, 344  
 intramural hematoma, 343  
 period of gestation and, 343  
 preceded by degeneration of aortic media, 343  
 stress of labor, 345

heredity, 338  
 incidence, 338  
 laboratory findings, 340-342  
 acid mucopolysaccharide levels, 341  
 aortic aberrations, 342  
 aortography and angiocardiology, 341  
 excretion of hydroxyproline, 340-341 and pregnancy, 342-347  
 skeletal manifestations of, 336-338  
 treatment, 342

Membrane rupture  
 premature, and estriol excretion, 552-554

Menouria, 478

Menstruation  
 contemporary beliefs, 226-231  
 maternal attitude, effect on child, 227-230  
 historical beliefs, 223-226  
 hyperthyroidism, effect of, on, 79  
 hypothyroidism, effect of, on, 79

Milk ejection reflex, 529, 601, 603

Müllerian duct, embryology of, 48, 49

Myomas of uterus, 52-55  
*See also* Uterus, myomas of

Nephrectomy, 429-432, 433, 449, 451-452

Nephrostomy, 432

Neurohypophysis. *See* Pituitary, posterior

Newborn, effect of scleroderma on, 284

**O**ligospermia  
 consistent, 123  
 definition of, 118  
 and hypermotility, 130

Osteogenesis imperfecta, 337

Ovary  
 adrenal and thyroid glands, effect on, 60  
 biochemistry of ovarian secretion, 59  
 cyclic changes in, 58-59  
 disorders of, nonendocrine, 66-68  
 endometriosis, 66-67. *See also* Endometriosis  
 inflammation, 67-68  
 gastrointestinal, and ovary, 67  
 ovarian abscess, 66-67  
 perioophoritis, 68  
 neoplasms, 68  
 hormone secretion. *See* Hormones, ovarian  
 inadequate luteal phase, 68-71  
 regulation of, 59-60

Stein-Leventhal syndrome, 62-66  
 clinical pattern and diagnosis of, 62-63, 64  
 laboratory findings, typical, 63  
 pathogenesis of, 63-65  
 treatment of, 65-66

Ovulation temperature graph, 113

Oxytocin, 528  
 chemistry of, 529  
 and milk ejection reflex, 529, 604  
 during pregnancy, 529-530  
 in puerperium, 530  
 uterine effect of, 529-530

Oxytocinase, 530

**P**ain  
*Gestalt* pain, 162  
 pathogenesis of, 161-162  
 levels of biologic pain-symbolization, 162  
 "pain spectrum," 162  
*See also* Pelvic pain

Pancreas  
 effect of pregnancy on, 518, 547

Papanicolaou staining technique, use of in seminal cytology, 119

Pelvic congestion syndrome, 164-165

Pelvic pain  
 psychogenic, 161-172  
 clinical findings, 168  
 diagnosis, 167-168  
 differential diagnosis, 168-170  
 hypno- and narcoanalysis in, 167-168  
 hysteria and hysterical personality, 162-164  
 pathology, 164-168  
 pelvic congestion syndrome, 164-165  
 prognosis, 172  
 prophylaxis, 172  
 treatment of, 169, 171

Pituitary  
 anterior  
 during pregnancy, 531-536  
 hormones of, 531-536  
 relationship to hypothalamus, 528  
 posterior  
 and ADH production, 530-531  
 function of, 529  
 and oxytocin production, 529-530  
*See also* Oxytocin  
 during pregnancy, 529-531

Placebos, 206-209  
 in pelvic pain, 171  
 side effects of, 208-209  
 in stressful situation, 208  
 toxic reaction to, 208

Placenta  
 endocrine activities of, 580-597  
 methods of investigation, 581-586  
 enzymes of, 574  
 estriol secretion and placental insufficiency, 560  
 as a homograft, 263-269  
 hypotheses for, 263-266  
 immunologically immature fetus, 263-264, 277  
 physiologic barrier between mother and fetus, 263, 264-265, 277  
 uterus as a privileged site, 263, 264, 277  
 weakened immunologic reactivity of mother, 263, 266, 277

perfusion in situ, 585  
 perfusion in vitro, 584-585  
 protein hormone secretion, 586-589  
 progesterone levels, 570-574  
 during labor, 571, 572  
 in early pregnancy, 571

postpartum, 572, 573  
 prior to labor, 571  
 and vasopressinase production, 531

Polyarteritis nodosa  
 classification of, 323  
 diagnosis, 329-330  
 etiology of, 322  
 initial morphologic changes, 322  
 and pregnancy, 324-332  
 effect on disease, 326-327  
 effect of delivery on, 331  
 fetal outcome, 328-329  
 historical review, 324-327  
 maternal outcome, 324-328  
 treatment of, 330-332  
 with cortisone, 330  
 effect on fetus, 331  
 remission of, 330  
 symptoms, 323-324, 329

Polycystic ovary syndrome. *See* Stein-Leventhal syndrome

Postcoital test (Sims-Huhner)  
 "immediate," 25  
 results, classification of, 24-25, 106, 122  
 time of, 24, 25

Pregnancy  
 adolescent response to, 149-150  
 collagen diseases in, 276-277  
 and dermatomyositis, 305-306  
 diabetes in, 547  
 endocrine function during, 267-269, 528-547  
 immune mechanisms in, 263-278, 271-272  
 and increase in protein-bound cortisol, 293  
 and Marfan syndrome, 342-347  
 pigmentary changes in, 534-535  
 and polyarteritis nodosa, 324-332  
 progesterone needs in, 536-539, 566  
 pyelonephritis in, 555-556  
 and rheumatoid arthritis, 276, 278, 286-301  
 and scleroderma, 280-284  
 steroid metabolism, 293  
 and SLE, 277, 288, 307-320  
 tests for, 91  
 phenothiazine derivatives, effect of, on, 213  
 reactions in, 91, 92  
 tranquilizers, use of during, 217-218  
 thymolymphatic system in, 266, 269-272

thymus during, 267  
 thyroid changes, 545-546

Progesterone  
 administration, 565  
 bioassay versus physicochemical data, 569-570  
 biologic activities of, 566  
 after delivery, 576  
 effects of, 525  
 fetal influences on metabolism of, 539, 574-577  
 guides to usage, 567-568  
 measurement, 525  
 during pregnancy, 536-539, 565-578  
 levels of 6-oxygenated compounds, 575-576  
 secretion of, 568  
 source of, 568-569  
 synthetic agents, 567  
 in combination with estrogens, 567  
 validity of studies on secretion of, 576-577

PSP test, 419

Pseudo-xanthoma elasticum, 337

Pyelonephritis  
 in pregnancy, 555-556  
 maternal urinary estriol level, 556

**R**aynaud's phenomenon and dermatomyositis, 304  
 Relaxin, 541-542  
 Rheumatoid arthritis, 274-275, 286-287  
 age incidence, 290  
 anemia in, 288  
 and delivery, 295  
 diagnosis of, 288-289  
 hereditary factors, 290-291  
 and lupus erythematosus, 275, 288  
 as manifestation of autoimmunity, 274-275, 277-278, 294  
 onset, 290  
 and pregnancy, 276, 291-295  
 amelioration of activity, 291-292, 330  
 mechanisms of effect, 292-295  
 changes in steroid metabolism, 293, 330  
 increase in protein-bound cortisol, 293  
 spontaneous jaundice, 293-294  
 onset, 291  
 exacerbation of symptoms, 291-292  
 relapse of disease following delivery, 291  
 prognosis of, 289-290  
 and renal disease, 287-288  
 rheumatoid factor, 289  
 transmission from mother to fetus, 295  
 rheumatoid nodule, 287  
 sex incidence, 290  
 treatment of, 294, 295-300  
 analgesic therapy, 296  
 bed rest, 295-296  
 blood transfusions, 294  
 chloroquine, 297  
 cortisol (Compound E), 298-300  
 estrogens, 294  
 gold, 297-298  
 indomethacin, 299-300  
 phenylbutazone, 299  
 progesterone, 294  
 salicylates, 296-297, 300  
 splinting of inflamed joints, 296  
 and rheumatoid arthritis, 275  
 serum LE factor, 275, 329  
 time of onset, 308

Rheumatoid factor, 289

Rubin test. *See* Tubes, fallopian, insufflation

**S**chauta-Amreich operation. *See* Hysterectomy, radical vaginal  
 Scleroderma  
 age incidence, 280  
 diagnosis of, 280-281  
 and newborn, 284  
 and pregnancy, 280-284  
 cardiovascular effects, 282  
 delivery, 283-284  
 gastrointestinal problems, 281-282  
 kidney effects, 282  
 nutritional problems, 282  
 skin effects, 281  
 prognosis for, 281  
 therapy of, 282-283  
 and toxic effect, 282, 283

Semen examination, 115-126, 129-130  
 cytology, seminal, 118-121  
 aspermia, 121  
 miscarriage, repeated, and, 129-130  
 pus cells, 134  
 spermatozoal structure, 119-121, 129-130  
 and varicocele, 123  
 ejaculate volume, 121-122, 129  
 specimen, obtaining of, 115-116  
 sperm count, 118, 123, 129, 130  
 sperm motility, 116-118, 123, 124, 129

continence, prolonged, effect on, 117-118, 125

hypophysectomy, effect on, 125

improvement of, by use of exogenous testosterone, 124-125

initial examination for, 116

and viscosity, high, 122-123

viscosity and agglutination, 122-123, 129

delayed liquefaction, 122

Sexual adjustment following radical pelvic surgery, 640-641

Shock

- in postoperative course, 636
- associated with infection, 637
- associated with hemorrhage, 636-637

Sling operation for restoration of urinary continence, 461-464

Somatotrophic hormone (STH). *See* Growth hormone

Spinnbarkeit, 16, 17, 22, 23

*See also* Cervix, mucus

Stein-Leventhal syndrome, 62-66

*See also* Ovary, Stein-Leventhal syndrome

Steroid(s)

- administration of, in placental studies, 582-583, 584, 586
- 17-ketosteroids, 527

*See also individual steroid hormones*

Stress syndromes in gynecology, 233-243

depression, 236-239

- Beck Inventory for measuring, 238
- clinical management, 238-239
- antidepressant drugs, use of, 239
- clinical picture of, 236-238
- laboratory tests, 237
- physical examination, 237
- symptoms, 237

hysteria, 239-242. *See also* Hysteria

schizophrenia, 242-243

tension, 234-236. *See also* Tension

Sucking reflex, 603-604

Surgery

- pelvic
- complications of, 771-785
- indications for, 611-612, 629, 706
- methods of urinary diversion in, 726-755
- operative care, 633-635
- postoperative care, 635-636
- postoperative complications and treatment, 636-641
- preoperative care, 629-633

total evisceration, 705-723

complications of, 782-785

indications for, 706

contraindications to, 706-707, 723

operative procedure, 707-722

- closure of pelvic peritoneum, 721-722
- deep pelvic dissection, 715, 718
- pelvic lymphadenectomy, 718-721
- urinary diversion, 711-715

Syphilis, 360-361

- chancre of, 360
- differential diagnosis, 360
- secondary, 361
- treatment of, 361

Systemic lupus erythematosus (SLE), 275-276

- and abortion, 277
- diagnostic criteria, 307-308
- postpartum activity of disease, 309
- and nephritis, 277
- and pregnancy, 277, 278, 307-320
- activity of disease, 308, 309, 310, 311-312, 314
- exacerbation of, 309, 310-312
- mild, 308
- moderately active, 308
- remission of, 309
- severe, 308
- adrenal cortical steroids, 319
- age of onset, 308
- effects of disease on conception, 312
- effects of disease on outcome, 312-319
- duration of disease, 318-319
- manifestations of disease, 314-318
- pattern of disease in multiple, 312 and prematurity, 277

Tension

- clinical management of, 235-236
- clinical picture of, 234-235
- psychological factors in, 222-232
- therapy for, 231
- premenstrual, 235
- symptomatic illness, 235

Thromboembolic disease, following radical pelvic surgery, 780, 782

Thymolymphatic system

- factors affecting function of, 266
- in normal pregnancy, 266, 269-272
- animal studies, 269-270

Thyroid gland

- effect of pregnancy on, 545-546

function in nonpregnant female, 527  
tests for, 527

Tissue, connective  
composition of, 334-336  
heritable disorders of, 336, 337  
*See also* Marfan syndrome

Toxemia of pregnancy  
differentiated from periarteritis nodosa, 330  
maternal estriol levels in, 554-555

Tranquilizers  
classification of, 209-216  
non-phenothiazine drugs, 213-216  
diphenylmethanes, 214  
miscellaneous, 214, 216  
propanediols, substituted, 214  
*Rauwolfia* alkaloids, 213-214  
phenothiazine derivatives, 209-213  
aliphatics (dimethylamines), 209, 210  
piperazine (piperazinyls), 209, 210  
piperidine (piperidyls), 209, 210  
side effects of, 210-213

combined-drug therapy, 218-219  
non-drug factors, role of, 199-209  
clinician and nursing team, 203-204  
interaction between patient and, 204-205  
environment, physical, 204  
patient, 200-203  
perception of drug by, 205-206  
psychologic structure of, 206  
placebo studies, 206-209  
side effects of administration, 208-209  
social setting, 204  
use of, in gynecology, 197-220  
evaluation of, 199  
in pregnant patient, 217-218  
in psychotic patient, 218  
selection of, 198-199  
in serious physical pathology, 216-217

Trophoblast, 266  
chorionic, 532-533

Tubes, fallopian, 32-46  
*hysterosalpingography*, 35-41. *See also* *Hysterosalpingography*  
insufflation, 32-35, 106  
contraindications for, 32-33  
duration of, 34  
in patency test, 33-35  
pregnancy after, incidence of, 35  
technique for, 33-35  
occlusions, types of, 42-45

surgery on, 41-46  
postoperative care, 45-46  
prerequisites for, 41-42  
technique of, 43-46  
timing of, 42

Tumors  
benign urethral, 363-364  
malignant urethral, 364-366  
radiosensitivity of, 619-621  
radiation response, 620  
sensitization response, 619-620

Twins, high oxytocinase levels and incidence of, 530

Uretersigmoidostomy, 434, 730, 733  
hyperchlormic acidosis incident to, 733-734  
operative technique, 736-737

Ureters  
anatomy of, 400, 401  
deliberate section of, 407-411, 432  
double, 386-387  
fistula of. *See* Fistula  
injury to  
bilateral, 384  
management during gynecologic surgery, 399-411  
prophylaxis, 402  
surgical treatment, 403-411  
management following gynecologic surgery, 413-452  
catheterization for, 417  
cystoscopy for, 417  
diagnosis, 415-417  
operations associated with, 401, 736-737  
pathologic conditions associated with, 401-402  
preoperative precautions, 399  
prevention of, in gynecologic surgery, 383-397  
following radiation therapy, 393-394  
recognition of, 402-403, 413-452  
review of literature, 384  
surgical trauma, 387-391  
types of, 385-387  
physiology of, 400-401  
obstruction, 413-414  
bilateral, 414, 440  
unilateral, 413-414, 440  
management of, 440-452  
typical features of, 289

Ureterostomy  
cutaneous, 726-730  
clinical examination, 726-727

operative technique, 727-730  
bilateral side-by-side, 729-730  
flank, 728-729

**Urethra**  
adenomas of, 363  
anatomy of, 355-356  
anomalies of, 356-358  
abnormal opening of ureter into urethra, 356  
absence of urethra, 356, 454-455  
congenital urethral strictures, 357-358  
duplication of, 356  
epispadias, 357, 454  
hypospadias, 356-357  
benign papillomas of, 363  
caruncle of, 363-364, 367  
diverticulum of, 369-375  
acquired, 369, 374  
congenital, 369  
diagnosis, 370-372  
medical treatment, 372  
recurrence of, 374  
surgical treatment, 372-375  
symptoms of, 369-370  
eversion and prolapse, 367  
hemorrhoids of, 366  
infections of, 359-363  
gonorrhea, 359-360  
periurethral abscess, 362-363  
postinfectious strictures, 367-368  
syphilis, 360-361  
trichomonial, 361-362  
malignant melanoma of, 364  
malignant tumors of, 364-366  
polyps of, 363  
primary carcinoma of, 365-366  
reconstruction of, 454-464  
by flap of vaginal mucosa, 455-458  
followed by sling operation, 461-464  
by mucosa of the urethral region, 458-460  
sarcoma of, 364-365  
strictures of, 367-368  
stripping of, 370, 371  
suburethral cyst, 366-367  
thrombosed veins, 366  
traumatic injury to, 358-359, 454  
venereal warts, 363

Urethrograms, 372

Urethroscopy, 370, 371, 372

Urinary diversion, 432, 434, 711-715, 726-755  
by cutaneous ureterostomy, 432, 434, 726-730

by ureterointestinal anastomosis, 730, 733-754

**Urinary incontinence**  
dribbling, 369  
stress, 369, 374  
sling operation for, 461

**Urinary tract**  
malformations of, 386-387

**Uterus**  
developmental anomalies of, 48-52  
and abortion, incidence of, 50  
prevention of, regimen for, 50, 52  
embryology of, 48  
endometriosis, 55-56  
*See also* Endometriosis  
malposition of, 56-57  
myomas of, 52-55  
and fertility, effect on, 52  
and miscarriages, incidence of, 52  
myomectomy, 53-55  
indications for, 53-54  
pregnancy after, incidence of, 53-54  
technique of, 54-55  
oxytocin, effect on, 529-530

**Vagina**  
cancer of, 614-616  
lymphatics of, 614-615

**Vulva**  
cancer of, 612-614  
surgical treatment of, 612-613

**Vulvectomy**  
radical, 642-658  
anesthesia for, 643  
complications of, 771-785  
lymphedema following, 656-657  
marginal necrosis of skin flaps following, 656  
slough of skin, 772-773  
vascular, 773-774  
end results, 657-658  
operative technique, 643-654  
dissection of groin, 645-647, 648  
final phase, 651-654, 655  
lymph node dissections, 647-650  
site of transverse incision, 643-644  
closing of, 651, 652  
postoperative management, 654, 656-657  
antibiotic therapy, 654, 656  
preoperative management, 642-643

**Wertheim operation, 609**  
for treatment of cervical cancer, 616

